I make a donation

CLOVIS-2

Pharmacogenetic cross-over trial on the response to different Clopidogrel loading doses depending on the presence of the CYP2C19*2 variant

Terminée

Remerciements de la Famille COLLET

Prix de Recherche Pr Jean-Philippe COLLET

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

objectif

Pharmacogenetic cross-over trial on the response to different Clopidogrel loading doses depending on the presence of the CYP2C19*2 variant

date de réalisation

2009

nombre de patients

109

nombre de centres participants

Monocentric (Pitié-Salpêtrière)

type de financement

Public (PHRC)

Référence

NCT00822666

Clopidogrel and Response Variability Investigation Study 2 (CLOVIS2)

Study Description

To evaluate the role of the genetic variant 2C19*2 on the pharmacodynamic response as assessed by optical aggregometry and on the pharmacokinetic response as assessed by measuring active metabolites following an oral administration of a loading dose of 300/900mg of clopidogrel in patients with established coronary artery disease.

source clinicaltrials.gov

Publications

CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
Jean-Sébastien Hulot, Jean-Philippe Collet, Guillaume Cayla, Johanne Silvain, Frédérick Allanic, Anne Bellemain-Appaix, Stuart A Scott, Gilles Montalescot
Publicated in Circulation : Cardiovascular Interventions
High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
Jean-Philippe Collet, Jean-Sébastien Hulot, Ghalia Anzaha, Ana Pena, Thomas Chastre, Claire Caron, Johanne Silvain, Guillaume Cayla, Anne Bellemain-Appaix, Jean-Baptiste Vignalou, Sophie Galier, Olivier Barthélémy, Farzin Beygui, Vanessa Gallois, Gilles Montalescot, CLOVIS-2 Investigators
Publicated in JACC : Cardiovascular Interventions

Autres études

ARCACHON

En cours

To demonstrate the non-inferiority of a strategy of simple clinical follow-up (without non-invasive stress testing) in asymptomatic CAD patients with a prior history of coronary revascularization comp...

ABYSS

En cours

Phase 4 trial, evaluating the interest of betablocking treatment in the long term treatment of non-complicated myocardial infarct.

AFIJI

En cours

Impact of genetics on occuring of coronary diseases in young patients and the pharmacogenetic of clopidogrel and its impact on the prognosis of patients having had angioplasty